Q3 2024 Aquestive Therapeutics Inc Earnings Call Transcript
Key Points
- Aquestive Therapeutics Inc (AQST) announced a major new product candidate, AQST-108, for alopecia areata, expanding their pipeline.
- The company completed a final adult study for their Anaphylm program and submitted a pre-NDA briefing book to the FDA, indicating progress towards regulatory approval.
- Libervant has achieved Medicaid coverage in all 50 states and agreements with two of the top three PBMs, enhancing market access.
- The OASIS study showed promising results for Anaphylm, with significant reduction in symptom resolution time, potentially differentiating it in the market.
- Aquestive Therapeutics Inc (AQST) reported a 22% increase in total revenues for the first nine months of 2024 compared to the same period in 2023, driven by licensing and royalty revenue.
- Despite revenue growth, the company reported a net loss of $11.5 million for the third quarter of 2024, an increase from the previous year.
- Research and development expenses increased significantly, driven by clinical trial costs and share-based compensation, impacting profitability.
- Selling, general, and administrative expenses rose due to increased commercial spending and regulatory fees, contributing to the net loss.
- The company faces uncertainties related to the regulatory approval and commercialization of its products, which could impact future performance.
- Legacy revenue streams, such as Suboxone, face potential dislocation due to market competition, posing a risk to future cash flow.
Good morning and welcome to the Aquestive Therapeutics, Third quarter, 2024 conference call.
(Operator Instructions)
I would now like to introduce your host for today's conference call, Bennett Watson of ICR Westwicke Investor Relations. You may begin.
Thank you, operator. Good morning and welcome to today's call on today's call. I'm joined by Daniel Barber, Chief Executive Officer and Ernie Toth, Chief Financial Officer. We're going to provide an overview of recent business developments and performance for the third quarter of 2024, followed by a Q&A session.
During the Q&A session. The team will be joined by Dr. Carl Kraus, Chief Medical Officer, Dr. Stephen Wargacki, Chief Science Officer and Sherry Korczynski, Senior Vice President of Sales and Marketing.
As a reminder, the company's remarks today correspond with the earnings release that was issued after market closed yesterday. In addition, a recording of today's call will be made available on Aquestive's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
